PitchSend

Investor Presentaiton

29 IDEAYA's Potential First-in-Class Synthetic Lethality DDR Pipeline Synthetic Lethality with Tumor-Promoting defects in DNA Repair Mechanisms IDE161 PARG Inhibitor Clinical Candidate GSK101 + Ф Pol Theta Helicase Inhibitor Development Candidate Werner Φ Helicase Inhibitor Preclinical Lead-Optimization Phase 1 First-in-Human Monotherapy in HRD Breast, Ovarian Potential to develop beyond HRD Phase 1 First-in-Human Q4 2023 Niraparib Combination in Tumors with HR Mutations and HRD Pursuant to GSK Collaboration, Option and License Agreement Targeting DC H2 2023 MSI-High Tumor Agnostic IDEAVA BIOSCIENCES

View entire presentation